Global Assembly Puts Off “Fake” Drug Definition Opposed By India
This article was originally published in PharmAsia News
Executive Summary
The World Health Assembly has rejected temporarily a global definition of what constitutes counterfeit drugs, providing relief to Indian generics makers. Indian health activists and the government feared the assembly would adopt a proposed definition that would cover generics as well as fake drugs as part of an effort to reduce the surfeit of counterfeits. The assembly suggested its executive board take a closer look at the International Medical Products Anti-Counterfeiting Taskforce definition opposed by Indian drug makers and their government. Their objection is to the part that determines a medical product counterfeit when "there is a false representation in relation to its identity, history or source, applying to the product, its container, packaging or other labeling information." (Click here for more
You may also be interested in...
There’s ‘No Silver Bullet’ For Making Medicines Packaging Sustainable
There’s no simple answer to the question of how to make medicines packaging sustainable, says international recycling consultancy and Veolia Group subsidiary Circpack. “Manufacturers need to assess what works best for them, and recyclers will do the same,” Circpack analyst and circular packaging expert Filipe Vieira de Castro tells HBW Insight in this exclusive Q&A. “The best thing we can all do is put effort into finding common ground between systems, which comes down to better understanding the complexities between them.”
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.